Bottom line
GGHCX vs QAAGZX: the short answer
GGHCX (INVESCO Health Care Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 57% by weight.
But QAAGZX is far broader, holding 277 positions to 82 for GGHCX, so beyond the top names it adds exposure GGHCX doesn't have.
QAAGZX is cheaper at 0.86% vs 1.07% — a difference of $21 a year per $10,000 invested.
Over five years, QAAGZX returned +4.1% a year vs +2.6% for GGHCX.
GGHCX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
GGHCX vs QAAGZX side by side
| GGHCX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Invesco | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.07% | 0.86% |
| Annual cost per $10k | $107 | $86 |
| 10-yr cost on $10k (prospectus) | $1,784 | $1,061 |
| Max front load | 5.5% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +9.2% | +18.1% |
| 5-yr return (annualized) | +2.6% | +4.1% |
| 10-yr return (annualized) | +5.8% | +9.0% |
| Best quarter | +19.6% | +23.4% |
| Worst quarter | −16.5% | −15.8% |
| Net assets (fund) | $1.2B | $751.7M |
| Number of holdings | 82 | 277 |
| Portfolio turnover | 59% | 65% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | GGHCX | QAAGZX | Difference |
|---|---|---|---|
| 2025 | +15.5% | +18.1% | −2.6% |
| 2024 | +4.0% | +1.7% | +2.3% |
| 2023 | +3.1% | +3.0% | +0.1% |
| 2022 | −13.5% | −12.5% | −1.1% |
| 2021 | +12.2% | +13.1% | −0.9% |
| 2020 | +14.5% | +29.6% | −15.2% |
| 2019 | +32.0% | +29.0% | +3.1% |
| 2018 | +0.5% | +1.1% | −0.7% |
| 2017 | +15.5% | +27.6% | −12.1% |
| 2016 | −11.7% | −10.5% | −1.2% |
Source: Fund prospectus bar charts
Holdings overlap
11 of GGHCX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | GGHCX | QAAGZX |
|---|---|---|
| Eli Lilly and Co. | 10.59% | 14.06% |
| Johnson & Johnson | 6.76% | 6.64% |
| UnitedHealth Group Inc. | 6.17% | 5.88% |
| Merck & Co., Inc. | 4.59% | 4.00% |
| AbbVie Inc. | 4.03% | 5.12% |
| Gilead Sciences, Inc. | 3.63% | 2.79% |
| CVS Health Corp. | 2.52% | 0.93% |
| Cardinal Health, Inc. | 2.10% | 1.04% |
| Guardant Health, Inc. | 2.04% | 1.22% |
| Vertex Pharmaceuticals Inc. | 2.01% | 2.26% |
| Thermo Fisher Scientific Inc. | 1.55% | 2.53% |
Source: SEC Form N-PORT
GGHCX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between GGHCX and QAAGZX?
Which is cheaper, GGHCX or QAAGZX?
Should I own both GGHCX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.